Spotlight Asset Group, Inc. Relmada Therapeutics, Inc. Transaction History
Spotlight Asset Group, Inc.
- $140 Million
- Q2 2024
A detailed history of Spotlight Asset Group, Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Spotlight Asset Group, Inc. holds 20,000 shares of RLMD stock, worth $68,000. This represents 0.04% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$68,000
Previous $93,000
35.48%
% of portfolio
0.04%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding RLMD
# of Institutions
88Shares Held
13.5MCall Options Held
85.8KPut Options Held
42.8K-
Vanguard Group Inc Valley Forge, PA1.26MShares$4.27 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.23MShares$4.2 Million0.12% of portfolio
-
Vestal Point Capital, LP New York, NY1.2MShares$4.08 Million0.27% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$4.06 Million0.01% of portfolio
-
Franklin Resources Inc San Mateo, CA1.01MShares$3.44 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $97.3M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...